Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Therapeutic evaluation of free and liposome-loaded furazolidone in experimental visceral leishmaniasis

Texto completo
Autor(es):
Tempone, Andre Gustavo [1] ; Mortara, Renato Arruda [2] ; de Andrade, Jr., Heitor Franco [3] ; Reimao, Juliana Quero [1]
Número total de Autores: 4
Afiliação do(s) autor(es):
[1] Inst Adolfo Lutz Registro, Dept Parasitol, Lab Appl Toxinol Antiparasit Drugs, BR-01246000 Sao Paulo - Brazil
[2] Escola Paulista Med, UNIFESP, Dept Microbiol Imunol & Parasitol, BR-0403902 Sao Paulo - Brazil
[3] Univ Sao Paulo, Lab Protozool, Inst Trop Med, BR-05603000 Sao Paulo - Brazil
Número total de Afiliações: 3
Tipo de documento: Artigo Científico
Fonte: INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS; v. 36, n. 2, p. 159-163, AUG 2010.
Citações Web of Science: 19
Resumo

Drug delivery systems are promising pharmaceutical formulations used to improve the therapeutic index of drugs. In this study, we developed a liposomal formulation of furazolidone that targets Leishmania (Leishmania) chagasi amastigotes in a hamster model. Using laser scanning confocal microscopy, it was demonstrated that the liposomal drug co-localised with L. (L.) chagasi amastigotes within macrophages. Liposomal furazolidone administered intraperitoneally at 0.5 mg/kg for 12 consecutive days reduced spleen (74%) and liver (32%) parasite burden at a 100-fold lower dose than the free drug. Free furazolidone (50 mg/kg) also effectively reduced spleen (82.5%) and liver (85%) parasites; its in vitro activity against promastigotes and intracellular amastigotes demonstrated a high degree of parasite selectivity. Thus, furazolidone, both in the free and liposome-loaded formulation, is an effective inhibitor of L. (L.) chagasi, representing a possible cost-effective drug candidate for the treatment of visceral leishmaniasis. (C) 2010 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved. (AU)

Processo FAPESP: 08/09260-7 - Combinações terapêuticas na leishmaniose visceral: o potencial anti-leishmania de bloqueadores de canais de cálcio e o uso de nanoformulações lipossomais
Beneficiário:André Gustavo Tempone Cardoso
Linha de fomento: Auxílio à Pesquisa - Regular